AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir,...
NORTH CHICAGO, Ill., Nov. 14, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data from its ongoing Phase 3b TOPAZ-II study evaluating VIEKIRA PAK®...
View ArticleAbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir,...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Nov. 14, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data from its ongoing Phase 3b TOPAZ-II study...
View ArticleAbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily...
NORTH CHICAGO, Ill., Dec. 2, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced its New Drug Application (NDA) has been accepted by the U.S. Food and Drug...
View ArticleAbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Dec. 2, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced its New Drug Application (NDA) has been accepted by the...
View ArticleEnanta Pharmaceuticals Announces U.S. Regulatory Approval of TECHNIVIE™...
(Source: Enanta Pharmaceuticals Inc) Enanta Pharmaceuticals Announces U.S. Regulatory Approval of TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) tablets The First and Only All-Oral Interferon-Free...
View ArticleAbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on...
NORTH CHICAGO, Ill., Oct. 1, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research-based biopharmaceutical company, today announced that 34 abstracts from its chronic hepatitis C clinical...
View ArticleAbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on...
NORTH CHICAGO, Ill., Oct. 1, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research-based biopharmaceutical company, today announced that 34 abstracts from its chronic hepatitis C clinical...
View ArticleAbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Oct. 1, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a global research-based biopharmaceutical company, today announced that 34 abstracts from its chronic...
View ArticleEnanta Pharmaceuticals Announces FDA Acceptance of AbbVie’s New Drug...
(Source: Enanta Pharmaceuticals Inc) Decision from FDA on New Drug Application anticipated in second half of 2016 Regimen contains Enanta’s lead protease inhibitor, paritaprevir WATERTOWN,...
View ArticleEnanta Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir,...
(Source: Enanta Pharmaceuticals Inc) AbbVie’s ongoing TOPAZ-II study evaluates long-term treatment outcomes in genotype 1a and genotype 1b chronic HCV patients with or without compensated cirrhosis...
View ArticleU.S. FDA Grants Priority Review to AbbVie for Supplemental New Drug...
NORTH CHICAGO, Ill., Jan. 7, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental...
View ArticleEnanta Pharmaceuticals Announces the U.S. FDA Grants Priority Review to...
(Source: Enanta Pharmaceuticals Inc) Priority review designation shortens the regulatory review period from the standard 10 months to six months TURQUOISE-III study showed 100 percent sustained...
View ArticleFDA Grants Priority Review to AbbVie for Supplemental New Drug Application...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Jan. 7, 2016/PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
View ArticleAbbVie Receives CHMP Positive Opinion for VIEKIRAX®...
NORTH CHICAGO, Ill., Feb. 26, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of...
View ArticleAbbVie Receives CHMP Positive Opinion for VIEKIRAX®...
NORTH CHICAGO, Ill., Feb. 26, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of...
View ArticleEnanta Announces the U.S. Food and Drug Administration has approved AbbVie’s...
(Source: Enanta Pharmaceuticals Inc) New once-daily, extended-release co-formulation contains the three direct-acting antiviral components of VIEKIRA PAK® for adult patients with genotype 1 (GT1)...
View ArticleEnanta Announces U.S. FDA has Approved AbbVie’s Supplemental New Drug...
(Source: Enanta Pharmaceuticals Inc) Approval supported by TURQUOISE-III study showing 100 percent SVR (N=60/60) in chronic hepatitis C virus (HCV) infected genotype 1b patients with compensated...
View ArticleAbbVie Announces High SVR Rates with VIEKIRAX®...
BARCELONA, Spain, April 14, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus...
View ArticleTECHNIVIE(TM) (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA...
- TECHNIVIE provides an opportunity to treat adults in the U.S. who have genotype 4 (GT4) chronic hepatitis C virus (HCV) infection without cirrhosis, a population historically considered...
View ArticleAbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives...
NORTH CHICAGO, Ill., Sept. 28, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved...
View ArticleAbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Sept. 28, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and...
View ArticleAbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir...
(Source: AbbVie Inc) Mar 30, 2016 NORTH CHICAGO, Ill., March 30, 2016 /PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 25 abstracts have been accepted for...
View ArticleAbbVie Announces Real-World Data with VIEKIRAX®...
BARCELONA, Spain, April 15, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505...
View ArticleEnanta Announces CHMP Grants Positive Opinion for an Eight-Week Treatment...
CHMP opinion is a step closer to the approval of an eight-week regimen of VIEKIRAX + EXVIERA for previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) patients with minimal to...
View ArticleEnanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s...
(Source: Enanta Pharmaceuticals Inc) AbbVie reports 98 percent of previously untreatedgenotype 1b (GT1b) chronic hepatitis C virus (HCV) infected patients without cirrhosis achieved SVRin Phase 3b...
View ArticleEnanta Announces High SVR Rates with AbbVie’s VIEKIRAX® + EXVIERA® Regardless...
(Source: Enanta Pharmaceuticals Inc) 100 percent of genotype 1b (GT1b) patients who received VIEKIRAX + EXVIERA without ribavirin for 12 weeks, achieved SVRin a post-hoc analysis,regardless of whether...
View ArticleTECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA...
(Source: AbbVie Inc) - TECHNIVIE provides an opportunity to treat adults in the U.S. who have genotype 4 (GT4) chronic hepatitis C virus (HCV) infection without cirrhosis, a population historically...
View ArticleTECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA...
NORTH CHICAGO, Ill., July 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global, research-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved...
View ArticleLupin Bolsters US Brands Portfolio with Methergine® Oral Tablets
MUMBAI, India and BALTIMORE, April 28, 2016 /PRNewswire/ -- The only FDA-approved oral uterotonic for the management of PPH, comes to market with a significant investment in professional medical...
View ArticleMerck Applauds the U.S. Department of Veterans Affairs (VA) for Broadening...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, applauds the U.S. Department of Veterans Affairs (VA) for broadening...
View ArticleMerck to Present New Findings from Chronic Hepatitis C Clinical Development...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the...
View ArticleMerck Announces Results From Phase 3 Studies of ZEPATIER(TM) (Elbasvir and...
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3 clinical trials evaluating ZEPATIER™ (elbasvir and grazoprevir)...
View ArticleMerck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3...
View ArticleAbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with...
- CHMP opinion brings AbbVie one step closer to approval of an eight-week regimen of VIEKIRAX + EXVIERA for previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) patients with minimal...
View ArticleMerck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from C-EDGE...
View ArticleMerck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
View ArticleBristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for...
(Source: Bristol-Myers Squibb Company) BMS-663068 is the first investigational antiretroviral designed to prevent HIV attachment to and entry into CD4+ T cells FDA Breakthrough Designation recognizes...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
(Source: Johnson & Johnson) July 23, 2015 Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir Filing Supported...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
TITUSVILLE, N.J., July 23, 2015 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the submission of a supplemental New Drug Application (sNDA) to the...
View ArticleYour Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV...
(Source: Johnson & Johnson) Notable HIV Advocates Highlight Perspectives of People Living with or Affected by HIV to Leverage Shared Support and Self-Expression TITUSVILLE, N.J., September 8, 2015...
View ArticleYour Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV...
TITUSVILLE, N.J., Sept. 8, 2015 /PRNewswire/ -- Seeking and sharing information are important parts of the HIV journey – in fact, 80 percent of people living with HIV said they give advice or tell...
View ArticleU.S. FDA Approves PREZISTA® (darunavir) for Use in Pregnant Women with HIV...
(Source: Johnson & Johnson) Data shows PREZISTA is a safe and effective treatment option in pregnant women, with no reports of mother-to-child HIV transmission among women who continued therapy...
View Article